ADMA Biologics, Inc.
ADMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $4 | $5 | $4 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $4 | $5 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 10% | 6.3% | -2.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 56.3% | 55.1% | 53.2% | 53.9% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 38.2% | 36.1% | 32.6% | 33.6% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 27.1% | 28.1% | 23.4% | 95.2% |
| EPS Diluted | 0.15 | 0.14 | 0.11 | 0.46 |
| % Growth | 7.1% | 27.3% | -76.1% | – |
| Operating Cash Flow | $0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | $0 |